NASDAQ:ECYT Endocyte (ECYT) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$23.99▼$23.9950-Day Range N/A52-Week Range$2.81▼$24.00VolumeN/AAverage Volume2.12 million shsMarket Capitalization$1.97 billionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial MediaProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media About Endocyte (NASDAQ:ECYT) StockEndocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.Read More Receive ECYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endocyte and its competitors with MarketBeat's FREE daily newsletter. Email Address ECYT Stock News HeadlinesMay 17, 2023 | thestreet.comThe Endocyte Bear Thesis: Why March Will be a Bad MonthJanuary 5, 2023 | thestreet.comWhy Endocyte (ECYT) Stock Is Plummeting in After-Hours Trading TodayMay 30, 2023 | Legacy Research (Affiliate) (Ad)The “Amazon Secret Royalty Program” Can Help Anyone Retire Like RoyaltyA unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.September 20, 2022 | finance.yahoo.comGlobal Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo FinanceJune 6, 2022 | globenewswire.comPurdue University impacting lives: successfully delivering innovations to the public - GlobeNewswireMay 23, 2022 | globenewswire.comGlobal Chronic Myeloid Leukemia Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - GlobeNewswireMay 20, 2022 | benzinga.comCortexyme Appoints Dr. Philip Low to Its Board of Directors - Benzinga - BenzingaMay 20, 2022 | streetinsider.comCortexyme (CRTX) Appoints Philip Low to Its Board - StreetInsider.comMay 30, 2023 | Legacy Research (Affiliate) (Ad)The “Amazon Secret Royalty Program” Can Help Anyone Retire Like RoyaltyA unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.May 3, 2022 | nasdaq.comNovartis Is Looking for Deals. Are These 3 Biotechs on Its List? - NasdaqApril 25, 2022 | seekingalpha.comClovis: Shifting Toward Nuclear Medicine - Seeking AlphaApril 14, 2022 | globenewswire.comGlobal Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Research Inc - GlobeNewswireJanuary 31, 2022 | globenewswire.comNon-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight - GlobeNewswireJanuary 27, 2022 | finance.yahoo.comGlobal Oncology Radiopharmaceuticals Market to Surpass US$ 5,206.8 Million by 2028, Says Coherent Market Insights (CMI) - Yahoo FinanceDecember 19, 2021 | proactiveinvestors.com.auRadiopharm Theranostics enhances management team skillset with three key appointments - Proactive Investors AustraliaNovember 2, 2021 | finance.yahoo.comFusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer - Yahoo FinanceNovember 2, 2021 | streetinsider.comFusion Pharmaceuticals Inc. (FUSN) Appoints Christopher Leamon as Chief Scientific Officer - StreetInsider.comSeptember 20, 2021 | streetinsider.comMirati Therapeutics (MRTX) Appoints David Meek as CEO - StreetInsider.comAugust 16, 2021 | afr.comTelix Pharma is on the cusp of first US FDA approval - The Australian Financial ReviewJuly 8, 2021 | wsj.comBiomedical Companies Inject Innovation Into Cancer Radiotherapy - The Wall Street JournalJune 24, 2021 | nytimes.comNew Therapy for Aggressive Prostate Cancer Improves Survival - The New York TimesJune 17, 2021 | nasdaq.comMcDonald's expands loyalty program to some New York City customers - NasdaqJune 17, 2021 | cnbc.comNovartis prostate cancer drug receives FDA breakthrough designation - CNBCJune 16, 2021 | nasdaq.comEXCLUSIVE-Workhorse to challenge USPS decision to award delivery contract to Oshkosh -- source - NasdaqJune 10, 2021 | prnewswire.comACELYRIN Announces Appointment of Patrick Machado, JD to Board of Directors - PRNewswireJune 8, 2021 | prnewswire.comMorphImmune, Inc., a Research Bridge Partners Portfolio Company, Appoints Ronald Martell as President and CEO - PRNewswireJune 2, 2021 | prnewswire.comMorphImmune, Inc. Appoints Ronald Martell as President and CEO - PRNewswireSee More Headlines Receive ECYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endocyte and its competitors with MarketBeat's FREE daily newsletter. Email Address ECYT Company Calendar Last Earnings11/07/2018Today5/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ECYT CUSIP29269A10 CIK1235007 Webwww.endocyte.com Phone765-463-7175FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,060,000.00 Net Margins-32,296.09% Pretax MarginN/A Return on Equity-21.19% Return on Assets-20.55% Debt Debt-to-Equity RatioN/A Current Ratio45.80 Quick Ratio45.80 Sales & Book Value Annual Sales$70,000.00 Price / Sales28,133.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.99 per share Price / Book12.06Miscellaneous Outstanding Shares82,090,000Free FloatN/AMarket Cap$1.97 billion OptionableOptionable Beta-0.01 Key ExecutivesMr. Michael A. Sherman (Age 52)CEO, Pres & Director Mr. Michael T. Andriole (Age 45)Chief Financial Officer Dr. Alison A. Armour (Age 54)Chief Medical Officer Dr. Christopher P. Leamon (Age 52)VP of R&D Dr. Philip S. Low (Age 70)Co-Founder, Chief Science Officer & Director Key CompetitorsPacira BioSciencesNASDAQ:PCRXSupernus PharmaceuticalsNASDAQ:SUPNCorcept TherapeuticsNASDAQ:CORTPerrigoNYSE:PRGOAcelyrinNASDAQ:SLRNView All Competitors ECYT Stock - Frequently Asked Questions How were Endocyte's earnings last quarter? Endocyte, Inc. (NASDAQ:ECYT) released its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The biopharmaceutical company earned $0.09 million during the quarter, compared to analyst estimates of $0.02 million. Endocyte had a negative net margin of 32,296.09% and a negative trailing twelve-month return on equity of 21.19%. What other stocks do shareholders of Endocyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endocyte investors own include Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Celldex Therapeutics (CLDX), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), Achaogen (AKAO), Bausch Health Companies (BHC) and Inovio Pharmaceuticals (INO). What is Endocyte's stock symbol? Endocyte trades on the NASDAQ under the ticker symbol "ECYT." What is Endocyte's stock price today? One share of ECYT stock can currently be purchased for approximately $23.99. How much money does Endocyte make? Endocyte (NASDAQ:ECYT) has a market capitalization of $1.97 billion and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. How can I contact Endocyte? Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The official website for the company is www.endocyte.com. The biopharmaceutical company can be reached via phone at 765-463-7175. This page (NASDAQ:ECYT) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endocyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.